News
Sementis CEO Dr Anne Collins is recipient of DMTC’s Collaboration Award
February 2024 Sementis was delighted to be recognised at the 2024 DMTC Annual Conference, and our CEO Dr Anne Collins...
November 2018
UK group Enesi Pharma has signed a deal with Australian biotech Sementis to develop solid dose versions of the latter’s lead peanut hypoallergy vaccine and its chikungunya/Zika vaccine candidates.
Read more from the PharmaTimes here.
News
February 2024 Sementis was delighted to be recognised at the 2024 DMTC Annual Conference, and our CEO Dr Anne Collins...
News
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
News
January 2023 Sementis has exciting news. We’re pleased to announce that we’ve been awarded a $3 million Federal...